OOIR: Observatory of International Research

Papers

(The TQCC of JACC: Cardiooncology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Editorial Board	127
Full Issue PDF	120
Full Issue PDF	110
Atrial Fibrillation in Patients With Cancer	110
Full Issue PDF	100
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	91
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	88
Epigenomics of Cardio-Oncology	87
Priorities in Cardio-Oncology	87
Hormonal Therapy and Cardiovascular Health	81
Cardiovascular Safety in Oncology Clinical Trials	63
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies	63
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	56
Cardiac Magnetic Resonance in Cardio-Oncology	56
Balancing Promise and Evidence	51
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	51
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	48
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	48
Full Issue PDF	47
Full Issue PDF	47
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	45
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	45
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	44
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	43
Cardiac Risk Stratification Before Lung Cancer Radiation	42

Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	41
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	41
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	40
Frailty	38
CARDIAC, MUSCULAR, AND NEUROLOGICAL TOXICITY SECONDARY TO PEMBROLIZUMAB IN A PATIENT WITH MELANOMA	38
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis	36
Permissive Cardiotoxicity	33
Cancer Immunotherapy Beyond Checkpoint Blockade	33
Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer	33
PROPORTIONATE AND ABSOLUTE PULMONARY EMBOLISM MORTALITY IN ONCOLOGY IN THE UNITED STATES FROM 1999-2019	32
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	32
The Need for an Early Biomarker of Cardiovascular Disease in Survivors of Hodgkin Lymphoma	31
Editorial Board/Officers Page	30
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	30
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	29
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	29
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	28
Leveling Up	27
Endothelin-1	27
Editorial Board	26
Full Issue PDF	25
SUCCESSFUL DIAGNOSIS AND SURGICAL RESECTION OF A PULMONIC SARCOMATOID CARCINOMA LACKING PET AVIDITY OR MALIGNANT APPEARING CMR TISSUE CHARACTERISTICS	25
TRASTUZUMAB CARDIOTOXICITY IN EARLY STAGE HER2 POSITIVE BREAST CANCER PATIENTS IN MEXICO	25
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	24
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	23
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	23
Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States	23
Developing a Model for Cross-Institutional Educational Collaborations	22
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	22
Quality-of-Care Measures for Cardio-Oncology	21
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	21
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	20
Vascular Complications of Atrial Fibrillation in Patients With Cancer	20
JACC: CardioOncology	20
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	18
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	18
A CHALLENGING CASE OF A LARGE RIGHT HEART MASS COMPLICATED BY COMPLETE HEART BLOCK	18
The United Kingdom’s First Cardio-Oncology Service	18
Assessing Silent Cardiotoxicity in Long-Term Lymphoma Survivors Treated With Radiotherapy	17
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer	16
Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent	16
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	16
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	15
Fluoropyrimidine Therapy in Gastrointestinal Cancer	15
Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	15
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	15
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	15
Low QRS Voltages in Cardiac Amyloidosis	14
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	14
CHA2DS2-VASc Score in Cardio-Oncology	14

Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	14
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	14
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	14
Post-Transplantation Cyclophosphamide	14
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	13
Cancer and Clot	13
To Adjudicate or Not Adjudicate	13
SEX DIFFERENCES IN ANTHRACYCLINE-TREATED CANCER SURVIVORS ASSESSED BY CARDIOVASCULAR MAGNETIC RESONANCE IMAGING	13
Full Issue PDF	13
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	13
Editorial Board	13
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	13
How to Perform Hematopoietic Stem Cell Transplantation	13
Hearts on the Minds of Oncologists	13
Donor-Derived Testicular Germ Cell Cancer in a Heart Transplant Recipient	12
Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors	12
Author Index	12
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	12
ABSTRACT WITHDRAWN	12
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	12
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	11
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	11
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	11
Cancer Therapy–Related Cardiac Dysfunction	11
Cardiovascular Considerations After Cancer Therapy	11
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	11
PALLIATIVE RESECTION OF A CARDIAC SARCOMA	10
Heart Transplantation in Adriamycin-Associated Cardiomyopathy in the Contemporary Era of Advanced Heart Failure Therapies	10
JACC: CardioOncology	10
PULMONARY VASCULAR TOXICITY WITH TYROSINE KINASE INHIBITOR THERAPY: A RARE CASE IN A CHRONIC MYELOID LEUKEMIA PATIENT	10
(Less) Time and Energy	10
PREVALENCE OF IMPAIRED CARDIORESPIRATORY FITNESS & ITS CONTRIBUTORS IN LUNG CANCER PATIENTS PRIOR TO RADIOTHERAPY	10
Clinical Practice Guidelines in Cardio-Oncology	10
Guiding Treatment With Recovered CTRCD	10
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	9
The Cause of Death in Patients With Cancer	9
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	9
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	9
Addressing the Overlooked	9
Navigating the Uncharted	9
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction	9
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	9
Reply	9
Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy	9
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	9
Reply	8
TYROSINE KINASE INHIBITOR ASSOCIATED POLYMORPHIC VENTRICULAR TACHYCARDIA	8
Preventing Cancer Therapy–Related Cardiotoxicity	8
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	8
ELECTROPHYSIOLOGIC PROPERTIES OF HEART BLOCK INDUCED BY IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS FROM CEMIPLIMAB	8
Editorial Board/Officers Page	8
Reply	8
Full Issue PDF	8
Learning From Trials	8
ASYMPTOMATIC CARDIAC METASTASIS OF NEUROENDOCRINE TUMOR DIAGNOSED BY PET CT SCAN	8
Reply	8
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	8
Amyloid Cardiomyopathy	7
When Clot Is Tumor	7
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	7
Assessing STEMI Outcomes in Patients With Cancer	7
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients	7
Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma	7
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	7
The ESC Cardio-Oncology Guidelines	7
Reply	7
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category	7
Reply	7
Overcoming LGBTQI+ Disparities in Cardio-Oncology	7
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	7
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	7
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	7
Full Issue PDF	7